ATO rejection leaves Careteq facing unresolved R&D tax exposure

Careteq will challenge the Australian Taxation Office’s rejection of its objections to amended assessments covering three financial years. The healthtech company says its R&D claims remain valid, but the dispute’s financial exposure and resolution timetable have not been disclosed.

  • ATO rejects objections to amended assessments for FY2021, FY2022 and FY2023
  • Careteq disputes the decision and maintains its R&D activities were eligible
  • Company plans to apply to the Administrative Review Tribunal within weeks
  • Financial exposure and timing of a resolution remain undisclosed
An image related to Careteq Limited A photo of the logo for Careteq Add us as a preferred source on Google
Image © middle. Logo © respective owner.

ATO Rejects Three Years of R&D Tax Objections

Careteq Limited (ASX:CTQ) is taking its dispute with the Australian Taxation Office to the Administrative Review Tribunal after the tax office rejected objections covering the company’s Research and Development Tax Incentive claims for the financial years ended 30 June 2021, 2022 and 2023.

The ATO’s decision relates to amended assessments issued in late May 2025. Careteq did not disclose the value of the assessments, the amount of tax in dispute, or any potential penalties or interest in Friday’s announcement, leaving the direct financial stakes unclear.

Careteq Maintains Its R&D Claims Were Eligible

Careteq said it disagrees with the ATO’s decision, based on advice from its legal advisers MinterEllison. The board maintains that the company’s R&D activities qualified for the incentive and that its claims for the three relevant years were valid.

The tax dispute remains part of the company’s financial clean-up as it concentrates on HMR Referrals. Careteq’s latest financial update described ATO dispute management alongside its strategic reset, which included selling its Embedded Health Solutions business and repaying debt.

Administrative Review Tribunal Application Planned

The board has resolved to apply to the Administrative Review Tribunal, an independent body that will reconsider the matter on its merits. Careteq expects to lodge the application over the next few weeks, but said the timing of a final resolution cannot yet be determined.

That makes the next meaningful disclosure procedural at first: confirmation that the application has been lodged. The more consequential question is whether Careteq later quantifies the potential cash or balance-sheet impact, or provides substantive detail on the merits review itself.

Get ASX:CTQ news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The planned review preserves Careteq’s challenge, but the unresolved assessment amount means the financial risk remains difficult to measure.

Questions in the middle?

  • How much tax, interest or penalties could ultimately be at stake?
  • When will Careteq formally lodge its Administrative Review Tribunal application?
  • Will the tribunal review produce a different finding on the eligibility of the claimed R&D activities?

Sources

1